P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment

Biomedicine and Pharmacotherapy

Volumn 65, Issue 3, 2011, Pages 151-156

  Zhao, Yi Fan ^a   Wang, Chong Ren ^a   Wu, Yan Ming ^a   Ma, Sheng Lin ^b   Ji, Yuan ^c   Lu, Yan Jun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Beta elemene; CDKs; Gefitinib; NSCLC; P21

Indexed keywords

BETA ELEMENE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; GEFITINIB; PROTEIN KINASE B; RNA;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959643897     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.02.009     Document Type: Article

References (26)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
2. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003, 290:2149-2158.
3. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2003, 304:1497-1500.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
5. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
6. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923.
7. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005, 102:3788-3798.
8. Lynch T.J., Bell D.W., Sordella R., Lynch T.J., Bell D.W., Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
9. Yao Y.Q., Ding X., Jia Y.C. Antitumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett 2008, 264:127-134.
10. Peng X.X., Zhao Y.L., Liang X.Y. Assessing the quality of RCTs on the effect beta-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp Clin Trials 2006, 27:70-82.
11. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993, 75:805-816.
12. Hengst L., Gopfert U., Lashuel H.A., Reed S.I. Complete inhibition of Cdk/cyclin by one molecule of p21 Cip1. Genes Dev 1998, 12:3882-3888.
13. Lu Y.J., Yamagishi N., Yagi T., Takebe H. Mutated p21WAF1/CIP1/SDI1 lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998, 16:705-712.
14. Stoppoloni D., Canino C., Cardillo I., Verdina A., Baldi A., Sacchi A., et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer 2010, 9:27-37.
15. Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 2006, 97:724-734.
16. Kurebayashi J., Okubo S., Yamamoto Y., Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 2004, 11:38-41.
17. Cheng Y.W., Wu M.F., Wang J., Yeh K.T., Goan Y.G., Chiou H.L., et al. Human Papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007, 67:10686-10693.
18. Tang J.J., Shen C., Lu Y.J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol Cell Biochem 2006, 291:139-144.
19. Pager C.T., Dutch R.E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J Virol 2005, 79:12714-12720.
20. Sun J.Z., Nam S., Lee C.S., Li B.Y., Coppola D., Hamilton A.D., et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001, 61:1280-1284.
21. Ji Y., Ma S.L., Zhang Y.P., Tang J.J., Wu Y.M., Lu Y.J. Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Anticancer Drugs 2009, 20:832-837.
22. Ma S.L., Tang J.J., Feng J.G., Xu Y.P., Yu X.M., Deng Q.H., et al. Induction of p21 (waf1) by p65 in p53 null cells treated with Doxorubicin. Biochimica et Biophysica Acta (Elsevier) 2008, 1783:935-940.
23. Bloom J., Amador V., Bartolini F., DeMartino G., Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003, 115:71-82.
24. Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J., Allday M.J. A degradation signal located in the C-terminus of p21 WAF1/CIP1 is a binding site for the C8 a-subunit of the 20S proteasome. EMBO J 2001, 20:2367-2375.
25. Zhu H.Y., Nie L.H., Maki C.G. Cdk2-dependent inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem 2005, 280:29282-29288.
26. Fukuchi K., Hagiwara T., Nakamura K., Ichimura S., Tatsumi K., Gomi K. Identification of the regulatory region required for ubiquitination of the cyclin kinase inhibitor, p21. Biochem Biophys Res Commun 2002, 293:120-125.